Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
ABSTRACT People living with Human Immunodeficiency virus (HIV) are up to 20 times more likely to develop active tuberculosis (TB) than people without HIV (PWoH). While anti-retroviral therapy (ART) has increased their health and lifespan, people with HIV (PWH) on ART are still at 4-5 fold greater risk for developing TB following infection with Mycobacterium tuberculosis (Mtb) compared to people without HIV (PWoH). However, why viral suppression and CD4 reconstitution following ART do not fully abrogate the risk of TB remains unclear. Residual inflammation present in PWH on ART has been linked to increased risk of co-infections and comorbidities. In addition, several lines of evidence show that PWH on ART have alterations in cellular metabolism, mainly within myeloid compartments, suggesting compromised abilities to mount effective immune responses to pathogens. A population of immunosuppressive cells termed myeloid-derived suppressor cells (MDSCs) has been implicated in dysfunctional immunity to HIV and Mtb infection. MDSCs were first described in cancer as negatively regulating tumor environments and suppressing NK and T cell functions. Higher frequencies of monocytic MDSCs (M- MDSC) were reported in PWH compared to PWoH, and M-MDSCs have been shown to expand after interruption of ART. Interestingly, M-MDSCs are also induced following Mtb infection but their role in anti-TB imunity in PWH on ART are not understood. We hypothesize that M-MDSCs suppress T cell functions and promote dysregulated immunometabolic responses to Mtb in PWH on ART. We propose to leverage bio-banked cryopreserved PBMC samples available through the Emory Center for AIDS research (CFAR) and our own archived samples, including from people with active and latent TB, with and without HIV. In Aim 1 we will employ multi-omic and immunologic approaches to derive an integrated MDSC biosignature associated with their suppressive functions and evaluate MDSC signature and frequencies in ART-naïve PWH, PWH on ART and PWoH. In Aim 2 we will test the hypothesis that expansion of M-MDSCs in PWH on ART contributes to ineffective immunity against Mtb-infection and promotes immunometabolic dysregulation. Our studies will bridge major knowledge gaps and provide a framework for targeting MDSCs to improve ART and advance HIV cure.
Grant Summary
Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $501K for university, nonprofit, healthcare org. Applications are due 2028-05-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $501K
2028-05-31
- 1Confirm your organization is eligible for Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH: Frequently Asked Questions
Who is eligible for the Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH?
Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH provide?
Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH provides up to $501K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH deadline?
Applications for Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH are due 2028-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH?
To apply for Immunometabolism of myeloid suppressor cell responses to M. tuberculosis in PWH, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.